Primary progressive multiple sclerosis: A 5-year clinical and MR study

Brain

Volumn 126, Issue 11, 2003, Pages 2528-2536

  Ingle, G T ^a   Stevenson, V L ^b   Miller, D H ^a   Thompson, Allan J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Atrophy; MRI; Multiple sclerosis; Primary progressive

Indexed keywords

ADULT; AGED; ARTICLE; BRAIN ATROPHY; CLINICAL FEATURE; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL DISABILITY; PRIORITY JOURNAL; RATING SCALE; RELAPSE; REMISSION;

EID: 0142153157     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awg261     Document Type: Article

References (39)

1. Barkhof F, van Walderveen M. Characterization of tissue damage in multiple sclerosis by nuclear magnetic resonance. Philos Trans R Soc Lond B Biol Sci 1999; 354: 1675-86.
2. Bergers E, Bot JCJ, De Groot CJA, Polman CH, Lycklama a Nijholt GJ, Castelijns JA, et al. Axonal damage in the spinal cord of MS patients occurs largely independent of T2 MRI lesions. Neurology 2002; 59: 1766-71.
3. Brex PA, Jenkins R, Fox NC, Crum WR, O'Riordan JI, Plant GT, et al. Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology 2000; 54: 1689-91.
4. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis N Engl J Med 2002; 346: 158-64.
5. Bruck W, Lucchinetti C, Lassmann H. The pathology of primary progressive multiple sclerosis. Mult Scler 2002; 8: 93-7.
6. Cottrell DA, Kremenchutzky M, Rice GP, Hader W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis. Brain 1999a; 122: 641-7.
7. Cottrell DA, Kremenchutzky M, Rice GP, Koopman WJ, Hader W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 1999b; 122: 625-39.
8. Cucurella MG, Rovira A, Rio J, Pedraza S, Tintore MM, Montalban X, et al. Proton magnetic resonance spectroscopy in primary and secondary progressive multiple sclerosis. NMR Biomed 2000; 13: 57-63.
9. Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122: 871-82.
10. Davie CA, Barker GJ, Thompson AJ, Tofts PS, McDonald WI, Miller DH. 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry 1997; 63: 736-42.
11. Filippi M, Campi A, Martinelli V, Rodegher M, Scotti G, Canal N, et al. A brain MRI study of different types of chronic-progressive multiple sclerosis. Acta Neurol Scand 1995; 91: 231-3.
12. Filippi M, Cercignani M, Inglese M, Horsfield MA, Comi G. Diffusion tensor magnetic resonance imaging in multiple sclerosis. Neurology 2001; 56: 304-11.
13. Goodkin DE, Hertsgaard D, Seminary J. Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests. Arch Phys Med Rehabil 1988; 69: 850-4.
14. Gronwall DM. Paced auditory serial-addition task: a measure of recovery from concussion. Percept Mot Skills 1977; 44: 367-73.
15. Hobart J, Freeman F, Thompson A. Kurtzke scales revisited: the application of psychometric methods to clinical intuition. Brain 2000; 123: 1027-40.
16. Ingle GT, Stevenson VL, Miller DH, Leary SM, Rovaris M, Barkhof F, et al. Two year follow-up study of primary and transitional progressive multiple sclerosis. Mult Scler 2002; 8: 108-14.
17. Kantarci OH, de Andrade M, Weinshenker BG. Identifying disease modifying genes in multiple sclerosis. J Neuroimmunol 2002; 123: 144-59.
18. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
19. Leary SM, Davie CA, Parker GJ, Stevenson VL, Wang L, Barker GJ, et al. 1H magnetic resonance spectroscopy of normal appearing white matter in primary progressive multiple sclerosis. J Neurol 1999a; 246: 1023-6.
20. Leary SM, Silver NC, Stevenson VL, Barker GJ, Miller DH, Thompson AJ. Magnetisation transfer of normal appearing white matter in primary progressive multiple sclerosis. Mult Scler 1999b; 5: 313-6.
21. Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ. Interferon β-1A in primary progressive MS: An exploratory randomized, controlled trial. Neurology 2003; 60: 44-51.
22. Lechner-Scott J, Kappos L, Hofman M, Polman CH, Ronner H, Montalban X, et al. Can the Expanded Disability Status Scale be assessed by telephone? Mult Scler 2003; 9: 154-9.
23. Losseff NA, Wang L, Lai HM, Yoo DS, Gawne-Cain ML, McDonald WI, et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 1996a; 119: 2009-19.
24. Losseff NA, Webb SL, O'Riordan JI, Page R, Wang L, Marker GJ, et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996b; 119: 701-8.
25. McDonnell GV, Hawkins SA. Primary progressive multiple sclerosis: increasing clarity but many unanswered questions. J Neurol Sci 2002; 199: 1-15.
26. McFarland HF, Barkhof F, Antel J, Miller DH. The role of MRI as a surrogate outcome measure in multiple sclerosis. Mult Scler 2002; 8: 40-51.
27. Miller DH, Leary S, Dehmeshki J, et al. Evidence for grey matter involvement in primary progressive MS: a magnetisation transfer imaging study. J Neurol 2001; 248: II/27.
28. Neuhaus O, Hartung HP. In search of a disease marker: the cytokine profile of primary progressive multiple sclerosis. Mult Scler 2001; 7: 143-4.
29. Rocca MA, Matthews PM, Caputo D, Ghezzi A, Falini A, Scotti G, et al. Evidence for widespread movement-associated functional MRI changes in patients with PPMS. Neurology 2002; 58: 866-72.
30. Stevenson VL, Miller DH, Rovaris M, Barkhof F, Brochet B, Dousset V, et al. Primary and transitional progressive MS: a clinical and MRI cross-sectional study. Neurology 1999; 52: 839-45.
31. Stevenson VL, Miller DH, Leary SM, Rovaris M, Barkhof F, Brochet B, et al. One year follow up study of primary and transitional progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2000; 68: 713-8.
32. Stevenson VL, Smith SM, Matthews PM, Miller DH, Thompson AJ. Monitoring disease activity and progression in primary progressive multiple sclerosis using MRI: sub-voxel registration to identify lesion changes and to detect cerebral atrophy. J Neurol 2002; 249: 171-7.
33. Thompson AJ, Kermode AG, MacManus DG, Kendall BE, Kingsley DP, Moseley IF, et al. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ 1990; 300: 631-4.
34. Thompson AJ, Kermode AG, Wicks D, MacManus DG, Kendall BE, Kingsley DP, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991; 29: 53-62.
35. Thompson AJ, Polman CH, Miller DH, McDonald WI, Brochet B, Filipi M, et al. Primary progressive multiple sclerosis. Brain 1997; 120: 1085-96.
36. Tortorella C, Viti B, Bozzali M, Sormani MP, Rizzo G, Gilardi MF, et al. A magnetization transfer histogram study of normal-appearing brain tissue in MS. Neurology 2000; 54: 186-93.
37. Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 1999; 12: 295-302.
38. van Walderveen MA, Lycklama a Nijeholt GJ, Ader HJ, Jongen PJ, Polman CH, Castelijns JA, et al. Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis. Arch Neurol 2001; 58: 76-81.
39. Wolinsky JS, Narayana PA, The PROMiSe Trial Study Group. Characteristics at entry into the glatiramer acetate study of primary progressive multiple sclerosis: the PROMiSe Trial. J Neurol 2001; 248: 134.